Hindustan Bio Sciences (532041) 주식 개요힌두스탄 바이오 사이언스는 인도의 제약 및 생명공학 분야에서 활동하는 회사입니다. 자세히 보기532041 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성1/6배당0/6위험 분석수익이 USD$1m 미만입니다(₹7M)의미 있는 시가총액이 없습니다(₹76M)모든 위험 점검 보기532041 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW482,882 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG482,882 investors already sharing narrativesYour Fair Value₹Current Price₹7.4081.4% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-23m36m2016201920222025202620282031Revenue ₹11.7mEarnings ₹2.1mAdvancedSet Fair ValueView all narrativesHindustan Bio Sciences Limited 경쟁사Nirman Agri GeneticsSymbol: NSEI:NIRMANMarket cap: ₹324.8mZenotech LaboratoriesSymbol: BSE:532039Market cap: ₹2.8bEmmessar Biotech & NutritionSymbol: BSE:524768Market cap: ₹124.9mBeryl DrugsSymbol: BSE:524606Market cap: ₹107.1m가격 이력 및 성과Hindustan Bio Sciences 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₹7.4052주 최고가₹9.9252주 최저가₹5.00베타-0.711개월 변동-5.73%3개월 변동-15.91%1년 변동-20.52%3년 변동27.15%5년 변동102.74%IPO 이후 변동3,600.00%최근 뉴스 및 업데이트공고 • May 19Hindustan Bio Sciences Limited to Report Q4, 2026 Results on May 30, 2026Hindustan Bio Sciences Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹8.18, the stock trades at a trailing P/E ratio of 56.7x. Average trailing P/E is 57x in the Biotechs industry in India. Total returns to shareholders of 107% over the past three years.공고 • Jan 19Hindustan Bio Sciences Limited to Report Q3, 2026 Results on Jan 31, 2026Hindustan Bio Sciences Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Jan 31, 2026공고 • Oct 16Hindustan Bio Sciences Limited to Report Q2, 2026 Results on Oct 31, 2025Hindustan Bio Sciences Limited announced that they will report Q2, 2026 results on Oct 31, 2025공고 • Aug 01Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: #31, sagar society, road no. 2, banjara hills, hyderabad - 500 034, hyderabad IndiaNew Risk • Aug 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.6% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.1% operating cash flow to total debt). Revenue is less than US$1m (₹7.2m revenue, or US$83k). Market cap is less than US$10m (₹94.3m market cap, or US$1.08m). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (4.6% net profit margin).더 많은 업데이트 보기Recent updates공고 • May 19Hindustan Bio Sciences Limited to Report Q4, 2026 Results on May 30, 2026Hindustan Bio Sciences Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹8.18, the stock trades at a trailing P/E ratio of 56.7x. Average trailing P/E is 57x in the Biotechs industry in India. Total returns to shareholders of 107% over the past three years.공고 • Jan 19Hindustan Bio Sciences Limited to Report Q3, 2026 Results on Jan 31, 2026Hindustan Bio Sciences Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Jan 31, 2026공고 • Oct 16Hindustan Bio Sciences Limited to Report Q2, 2026 Results on Oct 31, 2025Hindustan Bio Sciences Limited announced that they will report Q2, 2026 results on Oct 31, 2025공고 • Aug 01Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: #31, sagar society, road no. 2, banjara hills, hyderabad - 500 034, hyderabad IndiaNew Risk • Aug 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.6% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.1% operating cash flow to total debt). Revenue is less than US$1m (₹7.2m revenue, or US$83k). Market cap is less than US$10m (₹94.3m market cap, or US$1.08m). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (4.6% net profit margin).Reported Earnings • Aug 01First quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.08 in 1Q 2025)First quarter 2026 results: EPS: ₹0.01 (down from ₹0.08 in 1Q 2025). Revenue: ₹3.35m (down 21% from 1Q 2025). Net income: ₹140.0k (down 83% from 1Q 2025). Profit margin: 4.2% (down from 19% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth.공고 • Jul 21Hindustan Bio Sciences Limited to Report Q1, 2026 Results on Jul 31, 2025Hindustan Bio Sciences Limited announced that they will report Q1, 2026 results on Jul 31, 2025New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.1% operating cash flow to total debt). Revenue is less than US$1m (₹8.1m revenue, or US$94k). Market cap is less than US$10m (₹89.0m market cap, or US$1.03m). Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change).Reported Earnings • Jun 02Full year 2025 earnings released: EPS: ₹0.10 (vs ₹0.056 in FY 2024)Full year 2025 results: EPS: ₹0.10 (up from ₹0.056 in FY 2024). Revenue: ₹8.13m (down 23% from FY 2024). Net income: ₹1.01m (up 75% from FY 2024). Profit margin: 12% (up from 5.5% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.공고 • May 19Hindustan Bio Sciences Limited to Report Q4, 2025 Results on May 30, 2025Hindustan Bio Sciences Limited announced that they will report Q4, 2025 results on May 30, 2025공고 • Apr 23Hindustan Bio Sciences Limited Appoints Devanshu Ravinder Dange as Company Secretary and Compliance Officer, Effective April 23, 2025Hindustan Bio Sciences Limited announced that at the board meeting held on April 23, 2025 the board approved appointment of Mr. Devanshu Ravinder Dange as Company Secretary and Compliance Officer. Reason for Change: Appointed on account of resignation of the previous Company Secretary. Date of appointment is April 23, 2025. Brief Profile: Mr. Devanshu Ravinder Dange is an Associate Member of the Institute of Company Secretaries of India(ICSI). He holds Bachelor's Degree in Commerce from Osmania University. In addition, he is certified in Series XI - Merchant Banking from the National Institute of Securities Markets (NISM).Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹8.32, the stock trades at a trailing P/E ratio of 58.7x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 77% over the past three years.Valuation Update With 7 Day Price Move • Feb 28Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₹7.27, the stock trades at a trailing P/E ratio of 51.3x. Average trailing P/E is 46x in the Biotechs industry in India. Total returns to shareholders of 53% over the past three years.공고 • Jan 20Hindustan Bio Sciences Limited to Report Q3, 2025 Results on Jan 30, 2025Hindustan Bio Sciences Limited announced that they will report Q3, 2025 results on Jan 30, 2025New Risk • Jan 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (27% accrual ratio). Revenue is less than US$1m (₹12m revenue, or US$134k). Market cap is less than US$10m (₹104.7m market cap, or US$1.22m).공고 • Dec 31Hindustan Bio Sciences Limited Announces Resignation of Sukavasi Jyotsna as Company Secretary and Compliance OfficerHindustan Bio Sciences Limited informed that resignation of Mrs. Sukavasi Jyotsna (ACS 68536) for the post of Company Secretary and Compliance Officer has been approved. Date of Resignation: 31 December 2024.Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹11.50, the stock trades at a trailing P/E ratio of 45x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 171% over the past three years.공고 • Oct 17Hindustan Bio Sciences Limited to Report Q2, 2025 Results on Oct 30, 2024Hindustan Bio Sciences Limited announced that they will report Q2, 2025 results on Oct 30, 2024Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹9.61, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 33x in the Biotechs industry in India. Total returns to shareholders of 163% over the past three years.New Risk • Sep 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Revenue is less than US$1m (₹15m revenue, or US$177k). Market cap is less than US$10m (₹94.2m market cap, or US$1.13m). Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change).Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹9.58, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 36x in the Biotechs industry in India. Total returns to shareholders of 155% over the past three years.공고 • Jul 31Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2024Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2024, at 10:00 Indian Standard Time. Location: plot no,31, sagar, society, road no.2, banjarahills, hyderabad-500034, hyderabad India공고 • Jul 22Hindustan Bio Sciences Limited to Report Q1, 2025 Results on Jul 31, 2024Hindustan Bio Sciences Limited announced that they will report Q1, 2025 results on Jul 31, 2024공고 • May 12Hindustan Bio Sciences Limited to Report Fiscal Year 2024 Results on May 25, 2024Hindustan Bio Sciences Limited announced that they will report fiscal year 2024 results on May 25, 2024공고 • Jan 12Hindustan Bio Sciences Limited to Report Q3, 2024 Results on Jan 31, 2024Hindustan Bio Sciences Limited announced that they will report Q3, 2024 results on Jan 31, 2024공고 • Oct 20Hindustan Bio Sciences Limited to Report Q2, 2024 Results on Oct 31, 2023Hindustan Bio Sciences Limited announced that they will report Q2, 2024 results on Oct 31, 2023공고 • Sep 05Hindustan Bio Sciences Limited Announces Resignation of Goli Seshavataram, Chief Financial OfficerHindustan Bio Sciences Limited announced that Mr. Goli Seshavataram CFO, of the Company has tendered his resignation from the post of the CFO of the Company with effect from August 30, 2023.공고 • Aug 19Hindustan Bio Sciences Limited Appoints Sukavasi Jyotsna as Company Secretary and Compliance OfficerHindustan Bio Sciences Limited informed that appointment of Mrs. Sukavasi Jyotsna for the post of Company Secretary and Compliance Officer has been approved. Date of Appointment 18th August, 2023. Mrs. Sukavasi Jyotsna is an Associate Member of the Institute of Company Secretaries of India having membership No. ACS 68536. She holds Bachelor Degree in Commerce and having 1 years of experience in the field of Company Secretarial works.공고 • Aug 01Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2023Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2023, at 10:00 Indian Standard Time. Agenda: To approve the re-appointment of Mr. Venkata Rama Mohan Raju Jampana.공고 • May 19Hindustan Bio Sciences Limited to Report Q4, 2023 Results on May 30, 2023Hindustan Bio Sciences Limited announced that they will report Q4, 2023 results on May 30, 2023Board Change • May 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 5 highly experienced directors. Non Executive Independent Director Mantena Raju was the last director to join the board, commencing their role in 2010. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 01Third quarter 2023 earnings released: EPS: ₹0.05 (vs ₹0.002 loss in 3Q 2022)Third quarter 2023 results: EPS: ₹0.05 (up from ₹0.002 loss in 3Q 2022). Revenue: ₹3.18m (up 33% from 3Q 2022). Net income: ₹476.0k (up ₹496.0k from 3Q 2022). Profit margin: 15% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 37% per year, which means it is well ahead of earnings.공고 • Jan 23Hindustan Bio Sciences Limited to Report Q3, 2023 Results on Jan 31, 2023Hindustan Bio Sciences Limited announced that they will report Q3, 2023 results on Jan 31, 2023공고 • Jan 13Hindustan Bio Sciences Limited Announces Resignation of Varun Varma Jampana as Non Executive-Non Independent DirectorHindustan Bio Sciences Limited announced that Mr. Varun Varma Jampana, Non Executive-Non Independent Director of the company, vide his letter dated 12 January 2023 has tendered his resignation as Non Executive-Non Independent Director of the company with effect from 12 January 2023.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 6 highly experienced directors. Non-Executive Non-Independent Director Jampana Varma was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 03Second quarter 2023 earnings released: ₹0.07 loss per share (vs ₹0.05 loss in 2Q 2022)Second quarter 2023 results: ₹0.07 loss per share (further deteriorated from ₹0.05 loss in 2Q 2022). Net loss: ₹749.0k (loss widened 36% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.공고 • Oct 20Hindustan Bio Sciences Limited to Report Q2, 2023 Results on Oct 31, 2022Hindustan Bio Sciences Limited announced that they will report Q2, 2023 results on Oct 31, 2022공고 • Jul 30Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2022Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2022.공고 • Jul 19Hindustan Bio Sciences Limited to Report Q1, 2021 Results on Jul 29, 2022Hindustan Bio Sciences Limited announced that they will report Q1, 2021 results at 2:00 PM, Indian Standard Time on Jul 29, 2022Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 6 highly experienced directors. Non-Executive Non-Independent Director Jampana Varma was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 08Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: ₹0.002 loss per share (up from ₹0.11 loss in 3Q 2021). Revenue: ₹2.40m (up ₹2.39m from 3Q 2021). Net loss: ₹20.0k (loss narrowed 98% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 52% per year, which means it is well ahead of earnings.Reported Earnings • Nov 03Second quarter 2022 earnings released: ₹0.05 loss per share (vs ₹0.03 profit in 2Q 2021)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹524.0k (down 84% from 2Q 2021). Net loss: ₹550.0k (down 286% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 09First quarter 2022 earnings released: ₹0.07 loss per share (vs ₹0.05 profit in 1Q 2021)The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2022 results: Revenue: ₹1.94m (down 65% from 1Q 2021). Net loss: ₹754.0k (down 250% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 56% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 01Third quarter 2021 earnings released: ₹0.11 loss per share (vs ₹0.01 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹2.0k (down 100% from 3Q 2020). Net loss: ₹1.13m (down ₹1.28m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 76% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Dec 07New 90-day high: ₹3.33The company is up 16% from its price of ₹2.88 on 08 September 2020. The Indian market is also up 16% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 5.0% over the same period.Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 17% share price gain to ₹2.17, the stock is trading at a trailing P/E ratio of 13.4x, up from the previous P/E ratio of 11.5x. This compares to an average P/E of 61x in the Biotechs industry in Asia. Total returns to shareholders over the past three years are 309%.Is New 90 Day High Low • Nov 11New 90-day low: ₹1.73The company is down 6.0% from its price of ₹1.84 on 13 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.공고 • Jul 18Hindustan Bio Sciences Limited to Report Q1, 2021 Results on Jul 31, 2020Hindustan Bio Sciences Limited announced that they will report Q1, 2021 results on Jul 31, 2020주주 수익률532041IN BiotechsIN 시장7D0.7%9.0%1.9%1Y-20.5%11.2%-1.3%전체 주주 수익률 보기수익률 대 산업: 532041은 지난 1년 동안 12.9%의 수익을 기록한 Indian Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 532041은 지난 1년 동안 -1.4%를 기록한 Indian 시장보다 저조한 성과를 냈습니다.주가 변동성Is 532041's price volatile compared to industry and market?532041 volatility532041 Average Weekly Movement6.1%Biotechs Industry Average Movement9.1%Market Average Movement6.1%10% most volatile stocks in IN Market9.1%10% least volatile stocks in IN Market3.8%안정적인 주가: 532041는 지난 3개월 동안 Indian 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: 532041의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트19912Jampana Venkata Rama Rajuwww.hindustanbiosciences.in힌두스탄 바이오 사이언스는 인도에서 제약 및 생명공학 분야를 운영하고 있습니다. 이 회사는 재조합 인간 적혈구 생성 약물을 제공합니다. 또한 정제, 캡슐, 액제, 외용제, 시럽제 등 다양한 형태의 제품을 제공합니다.더 보기Hindustan Bio Sciences Limited 기초 지표 요약Hindustan Bio Sciences의 순이익과 매출은 시가총액과 어떻게 비교됩니까?532041 기초 통계시가총액₹75.86m순이익 (TTM)-₹789.00k매출 (TTM)₹7.37m10.3x주가매출비율(P/S)-96.1x주가수익비율(P/E)532041는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표532041 손익계산서 (TTM)매출₹7.37m매출원가₹4.49m총이익₹2.88m기타 비용₹3.67m순이익-₹789.00k최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)-0.077총이익률39.09%순이익률-10.70%부채/자본 비율284.4%532041의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/15 03:33종가2026/07/15 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Hindustan Bio Sciences Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • May 19Hindustan Bio Sciences Limited to Report Q4, 2026 Results on May 30, 2026Hindustan Bio Sciences Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹8.18, the stock trades at a trailing P/E ratio of 56.7x. Average trailing P/E is 57x in the Biotechs industry in India. Total returns to shareholders of 107% over the past three years.
공고 • Jan 19Hindustan Bio Sciences Limited to Report Q3, 2026 Results on Jan 31, 2026Hindustan Bio Sciences Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Jan 31, 2026
공고 • Oct 16Hindustan Bio Sciences Limited to Report Q2, 2026 Results on Oct 31, 2025Hindustan Bio Sciences Limited announced that they will report Q2, 2026 results on Oct 31, 2025
공고 • Aug 01Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: #31, sagar society, road no. 2, banjara hills, hyderabad - 500 034, hyderabad India
New Risk • Aug 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.6% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.1% operating cash flow to total debt). Revenue is less than US$1m (₹7.2m revenue, or US$83k). Market cap is less than US$10m (₹94.3m market cap, or US$1.08m). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (4.6% net profit margin).
공고 • May 19Hindustan Bio Sciences Limited to Report Q4, 2026 Results on May 30, 2026Hindustan Bio Sciences Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹8.18, the stock trades at a trailing P/E ratio of 56.7x. Average trailing P/E is 57x in the Biotechs industry in India. Total returns to shareholders of 107% over the past three years.
공고 • Jan 19Hindustan Bio Sciences Limited to Report Q3, 2026 Results on Jan 31, 2026Hindustan Bio Sciences Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Jan 31, 2026
공고 • Oct 16Hindustan Bio Sciences Limited to Report Q2, 2026 Results on Oct 31, 2025Hindustan Bio Sciences Limited announced that they will report Q2, 2026 results on Oct 31, 2025
공고 • Aug 01Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: #31, sagar society, road no. 2, banjara hills, hyderabad - 500 034, hyderabad India
New Risk • Aug 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.6% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.1% operating cash flow to total debt). Revenue is less than US$1m (₹7.2m revenue, or US$83k). Market cap is less than US$10m (₹94.3m market cap, or US$1.08m). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (4.6% net profit margin).
Reported Earnings • Aug 01First quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.08 in 1Q 2025)First quarter 2026 results: EPS: ₹0.01 (down from ₹0.08 in 1Q 2025). Revenue: ₹3.35m (down 21% from 1Q 2025). Net income: ₹140.0k (down 83% from 1Q 2025). Profit margin: 4.2% (down from 19% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth.
공고 • Jul 21Hindustan Bio Sciences Limited to Report Q1, 2026 Results on Jul 31, 2025Hindustan Bio Sciences Limited announced that they will report Q1, 2026 results on Jul 31, 2025
New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.1% operating cash flow to total debt). Revenue is less than US$1m (₹8.1m revenue, or US$94k). Market cap is less than US$10m (₹89.0m market cap, or US$1.03m). Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change).
Reported Earnings • Jun 02Full year 2025 earnings released: EPS: ₹0.10 (vs ₹0.056 in FY 2024)Full year 2025 results: EPS: ₹0.10 (up from ₹0.056 in FY 2024). Revenue: ₹8.13m (down 23% from FY 2024). Net income: ₹1.01m (up 75% from FY 2024). Profit margin: 12% (up from 5.5% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
공고 • May 19Hindustan Bio Sciences Limited to Report Q4, 2025 Results on May 30, 2025Hindustan Bio Sciences Limited announced that they will report Q4, 2025 results on May 30, 2025
공고 • Apr 23Hindustan Bio Sciences Limited Appoints Devanshu Ravinder Dange as Company Secretary and Compliance Officer, Effective April 23, 2025Hindustan Bio Sciences Limited announced that at the board meeting held on April 23, 2025 the board approved appointment of Mr. Devanshu Ravinder Dange as Company Secretary and Compliance Officer. Reason for Change: Appointed on account of resignation of the previous Company Secretary. Date of appointment is April 23, 2025. Brief Profile: Mr. Devanshu Ravinder Dange is an Associate Member of the Institute of Company Secretaries of India(ICSI). He holds Bachelor's Degree in Commerce from Osmania University. In addition, he is certified in Series XI - Merchant Banking from the National Institute of Securities Markets (NISM).
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹8.32, the stock trades at a trailing P/E ratio of 58.7x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 77% over the past three years.
Valuation Update With 7 Day Price Move • Feb 28Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₹7.27, the stock trades at a trailing P/E ratio of 51.3x. Average trailing P/E is 46x in the Biotechs industry in India. Total returns to shareholders of 53% over the past three years.
공고 • Jan 20Hindustan Bio Sciences Limited to Report Q3, 2025 Results on Jan 30, 2025Hindustan Bio Sciences Limited announced that they will report Q3, 2025 results on Jan 30, 2025
New Risk • Jan 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (27% accrual ratio). Revenue is less than US$1m (₹12m revenue, or US$134k). Market cap is less than US$10m (₹104.7m market cap, or US$1.22m).
공고 • Dec 31Hindustan Bio Sciences Limited Announces Resignation of Sukavasi Jyotsna as Company Secretary and Compliance OfficerHindustan Bio Sciences Limited informed that resignation of Mrs. Sukavasi Jyotsna (ACS 68536) for the post of Company Secretary and Compliance Officer has been approved. Date of Resignation: 31 December 2024.
Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹11.50, the stock trades at a trailing P/E ratio of 45x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 171% over the past three years.
공고 • Oct 17Hindustan Bio Sciences Limited to Report Q2, 2025 Results on Oct 30, 2024Hindustan Bio Sciences Limited announced that they will report Q2, 2025 results on Oct 30, 2024
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹9.61, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 33x in the Biotechs industry in India. Total returns to shareholders of 163% over the past three years.
New Risk • Sep 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Revenue is less than US$1m (₹15m revenue, or US$177k). Market cap is less than US$10m (₹94.2m market cap, or US$1.13m). Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change).
Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹9.58, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 36x in the Biotechs industry in India. Total returns to shareholders of 155% over the past three years.
공고 • Jul 31Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2024Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2024, at 10:00 Indian Standard Time. Location: plot no,31, sagar, society, road no.2, banjarahills, hyderabad-500034, hyderabad India
공고 • Jul 22Hindustan Bio Sciences Limited to Report Q1, 2025 Results on Jul 31, 2024Hindustan Bio Sciences Limited announced that they will report Q1, 2025 results on Jul 31, 2024
공고 • May 12Hindustan Bio Sciences Limited to Report Fiscal Year 2024 Results on May 25, 2024Hindustan Bio Sciences Limited announced that they will report fiscal year 2024 results on May 25, 2024
공고 • Jan 12Hindustan Bio Sciences Limited to Report Q3, 2024 Results on Jan 31, 2024Hindustan Bio Sciences Limited announced that they will report Q3, 2024 results on Jan 31, 2024
공고 • Oct 20Hindustan Bio Sciences Limited to Report Q2, 2024 Results on Oct 31, 2023Hindustan Bio Sciences Limited announced that they will report Q2, 2024 results on Oct 31, 2023
공고 • Sep 05Hindustan Bio Sciences Limited Announces Resignation of Goli Seshavataram, Chief Financial OfficerHindustan Bio Sciences Limited announced that Mr. Goli Seshavataram CFO, of the Company has tendered his resignation from the post of the CFO of the Company with effect from August 30, 2023.
공고 • Aug 19Hindustan Bio Sciences Limited Appoints Sukavasi Jyotsna as Company Secretary and Compliance OfficerHindustan Bio Sciences Limited informed that appointment of Mrs. Sukavasi Jyotsna for the post of Company Secretary and Compliance Officer has been approved. Date of Appointment 18th August, 2023. Mrs. Sukavasi Jyotsna is an Associate Member of the Institute of Company Secretaries of India having membership No. ACS 68536. She holds Bachelor Degree in Commerce and having 1 years of experience in the field of Company Secretarial works.
공고 • Aug 01Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2023Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2023, at 10:00 Indian Standard Time. Agenda: To approve the re-appointment of Mr. Venkata Rama Mohan Raju Jampana.
공고 • May 19Hindustan Bio Sciences Limited to Report Q4, 2023 Results on May 30, 2023Hindustan Bio Sciences Limited announced that they will report Q4, 2023 results on May 30, 2023
Board Change • May 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 5 highly experienced directors. Non Executive Independent Director Mantena Raju was the last director to join the board, commencing their role in 2010. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 01Third quarter 2023 earnings released: EPS: ₹0.05 (vs ₹0.002 loss in 3Q 2022)Third quarter 2023 results: EPS: ₹0.05 (up from ₹0.002 loss in 3Q 2022). Revenue: ₹3.18m (up 33% from 3Q 2022). Net income: ₹476.0k (up ₹496.0k from 3Q 2022). Profit margin: 15% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 37% per year, which means it is well ahead of earnings.
공고 • Jan 23Hindustan Bio Sciences Limited to Report Q3, 2023 Results on Jan 31, 2023Hindustan Bio Sciences Limited announced that they will report Q3, 2023 results on Jan 31, 2023
공고 • Jan 13Hindustan Bio Sciences Limited Announces Resignation of Varun Varma Jampana as Non Executive-Non Independent DirectorHindustan Bio Sciences Limited announced that Mr. Varun Varma Jampana, Non Executive-Non Independent Director of the company, vide his letter dated 12 January 2023 has tendered his resignation as Non Executive-Non Independent Director of the company with effect from 12 January 2023.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 6 highly experienced directors. Non-Executive Non-Independent Director Jampana Varma was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 03Second quarter 2023 earnings released: ₹0.07 loss per share (vs ₹0.05 loss in 2Q 2022)Second quarter 2023 results: ₹0.07 loss per share (further deteriorated from ₹0.05 loss in 2Q 2022). Net loss: ₹749.0k (loss widened 36% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.
공고 • Oct 20Hindustan Bio Sciences Limited to Report Q2, 2023 Results on Oct 31, 2022Hindustan Bio Sciences Limited announced that they will report Q2, 2023 results on Oct 31, 2022
공고 • Jul 30Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2022Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2022.
공고 • Jul 19Hindustan Bio Sciences Limited to Report Q1, 2021 Results on Jul 29, 2022Hindustan Bio Sciences Limited announced that they will report Q1, 2021 results at 2:00 PM, Indian Standard Time on Jul 29, 2022
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 6 highly experienced directors. Non-Executive Non-Independent Director Jampana Varma was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 08Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: ₹0.002 loss per share (up from ₹0.11 loss in 3Q 2021). Revenue: ₹2.40m (up ₹2.39m from 3Q 2021). Net loss: ₹20.0k (loss narrowed 98% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 52% per year, which means it is well ahead of earnings.
Reported Earnings • Nov 03Second quarter 2022 earnings released: ₹0.05 loss per share (vs ₹0.03 profit in 2Q 2021)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹524.0k (down 84% from 2Q 2021). Net loss: ₹550.0k (down 286% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 09First quarter 2022 earnings released: ₹0.07 loss per share (vs ₹0.05 profit in 1Q 2021)The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2022 results: Revenue: ₹1.94m (down 65% from 1Q 2021). Net loss: ₹754.0k (down 250% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 56% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 01Third quarter 2021 earnings released: ₹0.11 loss per share (vs ₹0.01 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹2.0k (down 100% from 3Q 2020). Net loss: ₹1.13m (down ₹1.28m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 76% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Dec 07New 90-day high: ₹3.33The company is up 16% from its price of ₹2.88 on 08 September 2020. The Indian market is also up 16% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 5.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 17% share price gain to ₹2.17, the stock is trading at a trailing P/E ratio of 13.4x, up from the previous P/E ratio of 11.5x. This compares to an average P/E of 61x in the Biotechs industry in Asia. Total returns to shareholders over the past three years are 309%.
Is New 90 Day High Low • Nov 11New 90-day low: ₹1.73The company is down 6.0% from its price of ₹1.84 on 13 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.
공고 • Jul 18Hindustan Bio Sciences Limited to Report Q1, 2021 Results on Jul 31, 2020Hindustan Bio Sciences Limited announced that they will report Q1, 2021 results on Jul 31, 2020
